Management of polypoidal choroidal vasculopathy: Experts consensus in Taiwan

Taiwan PCV consensus group

Research output: Contribution to journalReview article

Abstract

Polypoidal choroidal vasculopathy (PCV) is a prevalent retinal disease predominantly occurs in Asians that shares some similarities seen in neovascular age-related macular degeneration. Recent large multicenter clinical trials on intravitreal anti-vascular endothelial growth factor (VEGF) agents and photodynamic therapy (PDT) have shed lights on the management of PCV. The Taiwan National Health Insurance had granted limited anti-VEGF agents and PDT for patients with PCV after the approval of required data submission, especially fundus angiography, optical coherence tomography, and visual acuity. In order to best utilize these limited resources for the patients, an expert meeting was held to provide updated Taiwan consensus recommendations for the management of PCV, including initial therapy selection, assessment of treatment response, re-treatment/rescue treatment, and determination of treatment extension/follow-up schedule. An algorithm for treatment allocation under both initial and re-treatment setting was proposed. Further mechanistic and clinical studies are required to investigate the prognostic factors and optimal treatment protocols that will improve healthcare quality and reduce burden of disease and treatment for patients with PCV.

Original languageEnglish
JournalJournal of the Formosan Medical Association
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Taiwan
Consensus
Photochemotherapy
Therapeutics
Vascular Endothelial Growth Factor A
Retinal Diseases
Quality of Health Care
Optical Coherence Tomography
Macular Degeneration
National Health Programs
Clinical Protocols
Visual Acuity
Multicenter Studies
Appointments and Schedules
Angiography
Clinical Trials
Light

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{e951ef6a95d84efda291e8412268b22d,
title = "Management of polypoidal choroidal vasculopathy: Experts consensus in Taiwan",
abstract = "Polypoidal choroidal vasculopathy (PCV) is a prevalent retinal disease predominantly occurs in Asians that shares some similarities seen in neovascular age-related macular degeneration. Recent large multicenter clinical trials on intravitreal anti-vascular endothelial growth factor (VEGF) agents and photodynamic therapy (PDT) have shed lights on the management of PCV. The Taiwan National Health Insurance had granted limited anti-VEGF agents and PDT for patients with PCV after the approval of required data submission, especially fundus angiography, optical coherence tomography, and visual acuity. In order to best utilize these limited resources for the patients, an expert meeting was held to provide updated Taiwan consensus recommendations for the management of PCV, including initial therapy selection, assessment of treatment response, re-treatment/rescue treatment, and determination of treatment extension/follow-up schedule. An algorithm for treatment allocation under both initial and re-treatment setting was proposed. Further mechanistic and clinical studies are required to investigate the prognostic factors and optimal treatment protocols that will improve healthcare quality and reduce burden of disease and treatment for patients with PCV.",
author = "{Taiwan PCV consensus group} and Chen, {Lee Jen} and Cheng, {Cheng Kuo} and Ling Yeung and Yang, {Chang Hao} and Chen, {Shih Jen} and Chen, {Jiann Torng} and Chen, {San Ni} and Chen, {Wen Lu} and Sheng-Min Hsu and Hwang, {De Kuang} and Lai, {Chi Chun} and Lai, {Chien Hsiung} and Lee, {Fenq Lih} and Yang, {Chung May} and Wu, {Tsung Tien}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jfma.2019.04.012",
language = "English",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Excerpta Medica Asia Ltd.",

}

Management of polypoidal choroidal vasculopathy : Experts consensus in Taiwan. / Taiwan PCV consensus group.

In: Journal of the Formosan Medical Association, 01.01.2019.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Management of polypoidal choroidal vasculopathy

T2 - Experts consensus in Taiwan

AU - Taiwan PCV consensus group

AU - Chen, Lee Jen

AU - Cheng, Cheng Kuo

AU - Yeung, Ling

AU - Yang, Chang Hao

AU - Chen, Shih Jen

AU - Chen, Jiann Torng

AU - Chen, San Ni

AU - Chen, Wen Lu

AU - Hsu, Sheng-Min

AU - Hwang, De Kuang

AU - Lai, Chi Chun

AU - Lai, Chien Hsiung

AU - Lee, Fenq Lih

AU - Yang, Chung May

AU - Wu, Tsung Tien

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Polypoidal choroidal vasculopathy (PCV) is a prevalent retinal disease predominantly occurs in Asians that shares some similarities seen in neovascular age-related macular degeneration. Recent large multicenter clinical trials on intravitreal anti-vascular endothelial growth factor (VEGF) agents and photodynamic therapy (PDT) have shed lights on the management of PCV. The Taiwan National Health Insurance had granted limited anti-VEGF agents and PDT for patients with PCV after the approval of required data submission, especially fundus angiography, optical coherence tomography, and visual acuity. In order to best utilize these limited resources for the patients, an expert meeting was held to provide updated Taiwan consensus recommendations for the management of PCV, including initial therapy selection, assessment of treatment response, re-treatment/rescue treatment, and determination of treatment extension/follow-up schedule. An algorithm for treatment allocation under both initial and re-treatment setting was proposed. Further mechanistic and clinical studies are required to investigate the prognostic factors and optimal treatment protocols that will improve healthcare quality and reduce burden of disease and treatment for patients with PCV.

AB - Polypoidal choroidal vasculopathy (PCV) is a prevalent retinal disease predominantly occurs in Asians that shares some similarities seen in neovascular age-related macular degeneration. Recent large multicenter clinical trials on intravitreal anti-vascular endothelial growth factor (VEGF) agents and photodynamic therapy (PDT) have shed lights on the management of PCV. The Taiwan National Health Insurance had granted limited anti-VEGF agents and PDT for patients with PCV after the approval of required data submission, especially fundus angiography, optical coherence tomography, and visual acuity. In order to best utilize these limited resources for the patients, an expert meeting was held to provide updated Taiwan consensus recommendations for the management of PCV, including initial therapy selection, assessment of treatment response, re-treatment/rescue treatment, and determination of treatment extension/follow-up schedule. An algorithm for treatment allocation under both initial and re-treatment setting was proposed. Further mechanistic and clinical studies are required to investigate the prognostic factors and optimal treatment protocols that will improve healthcare quality and reduce burden of disease and treatment for patients with PCV.

UR - http://www.scopus.com/inward/record.url?scp=85065061465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065061465&partnerID=8YFLogxK

U2 - 10.1016/j.jfma.2019.04.012

DO - 10.1016/j.jfma.2019.04.012

M3 - Review article

AN - SCOPUS:85065061465

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

ER -